Lupin receives approval for Acotiamide Tablets to treat functional dyspepsia

22 Aug 2016 Evaluate

Lupin has received an approval for Acotiamide 100 mg Tablets from the Central Drugs Standard Control Organisation (CDSCO). The pharma major shall commence promoting the product in India shortly.

Acotiamide is a first-in-class novel drug to be introduced into the Indian Pharmaceutical Market (IPM) which could benefit millions of patients suffering from Dyspepsia or Indigestion, amongst the most common stomach complaints encountered in clinical practice. The molecule is a ‘Prokinetic’ agent - a type of drug which enhances gastrointestinal motility. Acotiamide enhances gastric accommodation and gastric emptying, the two factors which have been implicated in the cause of functional dyspepsia. Acotiamide is approved by PMDA Japan and is actively marketed in Japan.

The current market for plain Gastrointestinal (GI) prokinetics and combinations is estimated to be around Rs 2,640 crore growing at 14%. The overall GI market is estimated at Rs 11,438 crore which is growing at 13%, as per IMS MAT June 2016.


 

Lupin Share Price

2103.30 -8.70 (-0.41%)
01-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1720.40
Dr. Reddys Lab 1253.60
Cipla 1500.10
Zydus Lifesciences 914.50
Lupin 2103.30
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×